Vapen MJ Ventures Announces Listing on Frankfurt Stock Exchange

Vapen MJ Ventures Announces Listing on Frankfurt Stock Exchange

Vapen MJ Ventures (CSE: VAPN) (“Vapen MJ”) a fully integrated agricultural technology, services and property management company in the regulated cannabis industry, today announced that its common shares are now listed on the Frankfurt Stock Exchange (FSE) trading under the ticker symbol “VV5”. The Company continues to be listed on the Canadian Securities Exchange (CSE) under the ticker symbol “VAPN”.

Bob Brilon, president and chief financial officer of Vapen MJ Ventures, commented, “Listing the common shares of Vapen MJ Ventures on the Frankfurt Exchange is another important step in our evolution, helping increase awareness of our progress with the global investor community. The cannabis markets continue to expand around the world, and Vapen MJ is increasingly well-positioned to benefit from this growth. We recently announced our expansion outside of Arizona, with a partnership in Kentucky, and we expect additional progress in our efforts to diversify our revenues internationally. This listing is an obvious next step in our global expansion.”

About Vapen MJ Ventures

Vapen MJ, through its wholly-owned subsidiaries, currently operates in the US as an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (THC and CBD cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of high margin Cannabis THC and Hemp CBD products under the Vapen Brand.  Vapen MJ expansion plans include partnering with cannabis license holders and hemp farms in multiple states within the US.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vapen MJ’ periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of Vapen MJ.

Although Vapen MJ has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; are engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vapen MJ disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vapen MJ does not assume any liability for disclosure relating to any other company mentioned herein.

SOURCE Vapen MJ Ventures Corporation

View original content:

Bob Brilon, President and CFO, T: 602-620-9725, Investors@VapenMJ.comCopyright CNW Group 2019

Published at Fri, 14 Jun 2019 13:11:52 +0000

Texas gov signs bill expanding new conditions for medical marijuana use

Texas gov signs bill expanding new conditions for medical marijuana use

Texas Gov. Greg Abbott on Friday signed into law House Bill 3703, a measure that increases the number of qualifying patient conditions for medical cannabis use, which likely could increase dispensary sales in the state’s limited MMJ program.

The measure adds multiple sclerosis, Parkinson’s disease, ALS, terminal cancer, autism and many kinds of seizure disorders to the state’s list of qualifying MMJ conditions, according to The Dallas Morning News.

For more details on the bill, click here.

Published at Fri, 14 Jun 2019 23:14:14 +0000

Michigan Picks Up Pace of Reviewing and Awarding Marijuana Business Licenses

Michigan Picks Up Pace of Reviewing and Awarding Marijuana Business Licenses

LANSING – Since the Michigan Medical Marijuana Licensing Board was abolished at the end of April, the Marijuana Regulatory Agency has dramatically picked up the pace of reviewing business applications.

In May, the first full month of taking over licensing responsibilities, the MRA reviewed, and either approved, denied or gave preliminary approval to 213 license applications. In contrast, the licensing board, which was abolished earlier this year by Gov. Gretchen Whitmer, was considering an average of 95 applications a month.

As the state’s legal marijuana market for adult recreational use starts later this year, quick and efficient licensing will ensure that the market succeeds and thrives, MRA director Andrew Brisbo said Thursday, after the first public meeting of the MRA. 

Read more

Published at Fri, 14 Jun 2019 14:41:00 +0000

OrganiGram Holdings Inc (NASDAQ:OGI) And Pax Era Strike A Brand Partnership Deal

OrganiGram Holdings Inc (NASDAQ:OGI) And Pax Era Strike A Brand Partnership Deal

Cannabis industry player OrganiGram Holdings Inc (NASDAQ:OGI) has announced that it secured
a deal with Pax Era as one of its four partners in the launch of its products
in Canada.

Pax Era is the premium brand that sells oil vaporizers made
by a major consumer tech firm called PAX Labs, Inc. On the other hand,
OrganiGram has established itself as a leader in the production of cannabis
products. The deal between the two firms means OrganiGram will be among the
four partners that will play a part in Pax’s launch in Canada.

Pax plans to venture into the Canadian market before the end
of the year pending the legalization of cannabis concentrates in the North
American country. Organigram is an ideal partner for Pax because they both have
similar product portfolios that focus on class-leading technology that has the
potential to refine the vaping experience for Canadians.

“Innovative partnerships with exceptional companies like PAX mean our own product offering grows and our customers have access to cutting-edge technology and cannabis experiences,” stated Greg Engel.

Pax wants to be at
the top of the game as far as cannabis-based vape products are concerned

The deal with Pax aligns with Organigram’s commitment
towards achieving leadership and growth through the help of innovative
technologies. OrganiGram will provide Pax pods made by Edison Cannabis Co. so
that they can be distributed by its provincial partners in the coastal region.
The entire sales and distribution process will be carried out in line with
extractable products legislation in Canada.

Organigram has been busy developing an impressive portfolio
of concentrate in preparation for Cannabis 2.0 vape pens as well as edibles
which are scheduled to launch later this year. Engel noted that his company’s
team has constantly been working on improving and producing products that will
please customers.

Canada is one of the fastest growing markets for cannabis
products courtesy of legalization efforts. This makes it an attractive market
for many companies that deal with the cannabis industry. Pax Era aims to secure
a steady market for its products in the country with OrganiGram’S help.

Published at Fri, 14 Jun 2019 12:01:05 +0000

5 Cannabis Stats Every Entrepreneur Should Know

5 Cannabis Stats Every Entrepreneur Should Know

eCann Media is proud to showcase our portfolio of investments and subsidiaries. We have completed numerous investments across multiple verticals and sectors in the cannabis industry. Requesting an invitation will enable the eCann team to consider your eligibility for investment as well help us to identify the opportunities that best fit your needs and investment objectives.

Published at Fri, 14 Jun 2019 13:30:00 +0000

Why Mood-Based Cannabis Products Are About to Blowup

Why Mood-Based Cannabis Products Are About to Blowup

eCann Media is proud to showcase our portfolio of investments and subsidiaries. We have completed numerous investments across multiple verticals and sectors in the cannabis industry. Requesting an invitation will enable the eCann team to consider your eligibility for investment as well help us to identify the opportunities that best fit your needs and investment objectives.

Published at Fri, 14 Jun 2019 18:00:00 +0000

Female Founders in Their 50s Are Starting Cannabis Companies to Take Care of Their Own

Female Founders in Their 50s Are Starting Cannabis Companies to Take Care of Their Own

Jennifer Chapin, the cofounder of Kikoko, recently recalled how she was “laughed out of the dispensaries” when she tried to sell her low-dose cannabis-infused teas in her company’s early days. Three years later, Kikoko’s teas, which come in sachets and canisters wrapped with pink-and-purple stripes and cartoon flowers promising benefits such as “Sensuali-tea” and “Tranquili-tea,” are sold through over 300 storefronts and delivery services across California.

“We are a women-centric, women-owned, women-operated company,” Chapin declared to a room full of women at Arcview, a conference for cannabis investors, in Los Angeles in February. “By women, for women.”

Arcview welcomes investors irrespective of gender, but Kikoko had sponsored a women-only “tea party” (with unmedicated tea) to facilitate some female-friendly networking and announce that the company was seeking capital for expansion into new product categories, with minimum investments starting at $1 million.

Courtesy, Kikoko

Founders of female-focused cannabis startups like Kikoko may soon be laughing all the way to the bank—and they’re getting there by looking beyond millennials, and catering to women in their 40s, 50s, and beyond. Executives such as Chapin, who is 55, are listening to older women’s wishes for low-dose cannabis products that address concerns such as sleep, anxiety, and sexual pleasure, and positioning their companies at the very lucrative intersection of women, weed, and wellness.

Wellness, women, and weed

It’s a market that’s growing. Women control the majority of household purchases, and according to the US Consumer Expenditure Survey, single women over 45 spend about $640 per year on personal care items and $400 annually on drugs. As legalization takes hold, those products are increasingly likely to contain—or even be replaced by—cannabis. According to sales data and a survey of 4,000 cannabis consumers by the San Francisco-based delivery platform Eaze, the number of female cannabis consumers nearly doubled in 2018, and with their growth outpacing men, women are on track to be half of the cannabis market by 2022. Female baby boomers on the platform grew by nearly a quarter between 2017 and 2018.

Kimberly Kovacs, the cofounder and CEO of MyJane, which delivers “curated cannabis” boxes  to women (think Birchbox-meets-Eaze), was also at Arcview. That same week, her company was acquired by the cannabis logistics conglomerate MJIC for an undisclosed sum, after completing just three weeks of deliveries. MJIC CEO Sturges Karban was unabashed about the acquisition’s main attraction.

“Women are the new targets of the adult-use cannabis wellness sector,” wrote Karban, in a press release. “Yet their needs are not being addressed by the cannabis industry.”

“We don’t call that micro-dosing. We just call that normal.”

Getting stoned is not chief among those needs, Kovacs found when MyJane conducted a survey of women in Orange County, CA. When I asked what was, she didn’t skip a beat: “Sleep,” she said. “100%.”

“I don’t want to take an Ambien,” said Kovacs, who is 52, with blonde hair and clear blue eyes. “I don’t even want to take Melatonin … half a cup of tea, I sleep through the night.” (MyJane includes Kikoko tea amongst its offerings in its boxes.)

Courtesy, MyJane

In addition to better sleep, women told MyJane they were seeking relief from pain, anxiety, and stress. Many hadn’t used cannabis before and said they wanted their THC—the chemical compound that results in feeling high—in very low doses.

“By the way, we don’t call that micro-dosing,” said Kovacs. “We just call that normal.”

Ding-dong, Avon calling

Both Chapin and Kovacs referenced Avon—the 135-year-old cosmetics company known for its door-to-door saleswomen. “I don’t want to go to a dispensary,” said Kovacs. “I don’t even want to go to the grocery store anymore!”

“I don’t want to go to a dispensary. I don’t even want to go to the grocery store anymore!”

Instead, these companies strive to deliver both products and education in personal and familiar settings, outside dispensaries. Part of what they’re doing is teaching their customers how to use the range of new products available in the sector.

MyJane’s customers create online profiles answering questions about their symptoms, food allergies, preferences, and prior experience with cannabis. Then, a female “ambassador” from the company arrives at a customer’s doorstep on the agreed-upon date and time to deliver a box of selected products and walk the recipient through each one.

Kikoko’s teas are sold via dispensaries and delivery services, but the company also holds tea parties which include a “cannabis 101” slideshow about the plant’s history and benefits. Chapin estimates that in 2018, the company held over 100 of these events in private homes, country clubs, and retirement communities throughout California. (It was at a Kikiko tea party in Santa Monica that Chapin and Kovacs first met.)

Courtesy, Kikoko

Anyone for a cuppa?

Kikoko’s website has a page for people who want to host their own “High Tea Parties,” complete with downloadable images for invitations, tips (take public transit), and a Pinterest page of suggested menu items.

“We envision an army of women throughout the state of California,” said Chapin, of the consumers she hopes to recruit into hosting high teas.

Bridgett Davis, the founder of the Los Angeles-based cannabis topicals brand Big Momma’s Legacy, is also building a business based on older women customers—using a similar model of cohosting tea parties with local cannabis brands at private homes to slowly build her business from the ground up.

“It’s a group of maybe 10 to 15 of my golden girls,” she said of a typical event. “I have a variety of clients, from white ladies in Brentwood to old grandmas in Compton.”

Quartz/Jenni Avins

Bridgett Davis, the founder of Big Momma’s Legacy.

Davis agreed that a familiar setting and privacy were crucial to her customers, who use her salve and roll-on oil to ease the pain of rheumatism and sciatica, and said she’s counting on her “golden girls” to help her grow her business.

“I cannot ask for better brand ambassadors, and they’re not paid,” she said. “It’s grass-roots, and I’m building it bit by bit. When one of my seniors talks to their friend, their friend is listening.”

Riding the wellness wave

With the global wellness industry now worth an estimated $4 trillion worldwide, it’s little wonder that cannabis companies such as MyJane, Kikoko, and countless others position themselves as purveyors of supplies for self-care rather than recreation. And women—especially those in middle-age—are frequently caring not only for themselves, but also for their friends, children, and aging parents. (Kovacs told me she supplies her father with topicals for his arthritis, and her mother with tea for sleeping.) No wonder they’re tired.


Don’t bogart that joint, girlfriend.

Both Kovacs and Chapin came to cannabis by way of a woman close to them suffering as a result of cancer. In Kovacs’ case, it was her mother-in-law, who eased her post-surgery pain and reduced her opioid use with cannabis. In Chapin’s, it was a dear friend who used edibles to aid her sleep and appetite, but was getting pummeled by high dosages. Both women saw the opportunity for products that spoke to women’s wellness.

Plus, noted MyJane cofounder Cara Raffele, “There’s a trust gap in healthcare for women.” Indeed, as Quartz’s Annaliese Griffin has written, that trust gap has made women particularly receptive to wellness brands that address their health concerns, respect their pain, and speak to them personally.

During her presentation at Arcview, Chapin said at one point, “we’re really tired of taking Ambien.” A women near me whispered under her breath: “That’s so me.”

Published at Mon, 20 May 2019 21:58:56 +0000

Relevium Technologies Continues To Advance Its Fundamental Story In Both The THC and CBD Verticals

Relevium Technologies Continues To Advance Its Fundamental Story In Both The THC and CBD Verticals

Earlier this year, we issued an update on Relevium Technologies (RLV.V) (RLLVF) and believe that this is an opportunity to be following. The last month has been quite busy for the company and we are excited about the recent developments. Relevium represents a multi-faceted growth opportunity that is working to capitalize on some of the most attractive verticals of the cannabis industry.

One of the reasons we are excited about Relevium is due to its attractive operating structure and we believe that this enhances its overall growth prospects. Currently, the company operates through two wholly-owned subsidiaries which we have highlighted below:

  • BGX E-Health LLC (BGX): BGX markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix brand portfolio in the United States and Europe. Bioganix is currently being sold by some of the world’s largest retailers including and
  • Biocannabix Health Corporation (BCX): BCX is focused on creating a vertically integrated medical cannabis company for the endo-medicinal products for pediatric care into the Canadian market.

Through a series of  growth initiatives, Relevium has been developing a premium line of products and we are favorable on the continued execution. The company’s strategy for developing and growing its brands includes expanding its product offerings, adding new distribution channels, and developing partnerships that add value through exclusive formulations.

Although Relevium has been able to significantly advance its fundamental story, the market has not responded accurately to the recent developments and we believe that this opportunity is flying under the radar. During the last month, the company has recorded some major milestones and we have provided an update on      the latest developments.

Reports a Significant Investment and Planned Acquisition

Last week, Biocannabix executed a letter of intent to acquire 30% of Weedsense Inc., a late stage applicant for standard processing and federal medical sales licenses. Weedsense is building a wholesale and distribution business in Montreal and will be working with licensed producers/processors and will be distributing directly to medical patients through a network of pharmacies and clinics. Weedsense also plans to service the recreational market by acting as a distributor to provincially-sanctioned wholesalers such as the Ontario Cannabis Store (OCS) or Société Québécoise du Cannabis (SQDC).

Weedsense can also act as a secured third-party logistics (3PL) partner for other market participants who seek direct access to the Quebec market for their products. Weedsense has applied for a standard processing and medical sales licenses through Health Canada and is constructing an EU GMP compliant facility in Montreal. Weedsense expects to be fully licensed by the fourth quarter of 2019 and obtain the EU GMP certification shortly after.

The investment into Weedsense provides Biocannabix with the capability to import, export, warehouse, package and sell directly to medical patients      and hospitals in a secure and compliant manner. Under the agreement, Biocannabix has the option to acquire 100% of Weedsense after the granting of the licenses by Health Canada. One of the reasons we are favorable on this transaction is because it is conditional on the granting of the licenses by Health Canada. This relationship will help Biocannabix in its mission to become a leader in providing safe, organically sourced endo-medicinal products for pediatric care int      the Canadian market. T     his could prove to be a major value driver to the entire business.

The idea behind Weedsense from the beginning has been to offer patients the best possible service as well as fairly priced premium products. We believe that the cannabis industry needs a patient centric wholesale/distribution platform and we will monitor how the team is able to execute on this.

Issues Update on its Cannabis and CBD Strategy

Earlier this month, Relevium released an update on its positioning and strategy regarding       medical cannabis and      CBD market opportunities     . This update came after the FDA held a public hearing on      its role in regulating cannabis-derived products such as CBD as nutritional supplements.

The FDA’s position is that although hemp is no longer an illegal substance under federal law, the FDA continues to regulate cannabis products under the Food, Drug, and Cosmetic Act (FD&C) and Section 351 of the Public Health Service Act. Therefore, and until their position changes, any cannabis product marketed with a claim of therapeutic benefit, regardless of whether it is hemp-derived, must be approved by the FDA before it can be sold. The statement also confirms that the addition of CBD to food products and dietary supplements is unlawful.

The public hearing was the first of many steps towards allowing CBD as a supplement, which would then allow companies like Relevium, who fall under the supplement jurisdiction of the FDA, to provide current and future customers with trusted nutraceutical formulations containing full-spectrum CBD through its LeefyLyfe and Bioganix brands across the US.

Under the FD&C Act, cosmetic products and ingredients are not subject to pre-market approval as long as the product does not make a health claim. This is important since the company is also testing skin care formulations under its Push and Pull brand formulated with CBD. This is something we are watching since the new skin care line is expected to serve as a major growth driver for the Bioganix family of products.

The European authorities in Europe and the UK have taken similar positions to the US by allowing the sale of full-spectrum hemp oil and hemp CBD as long as no medical claims are made. We have been bullish on the European CBD opportunity due to size of the population and the existing demand for these products.

In Germany, in order to be able to make a medical claim, companies have to register their products with the health authorities to obtain a PZN (Pharma-Zentral-Nummer), which is a national code for medicine identification across Germany. A PZN is needed for a company to make health claims and for the company’s products to be sold through pharmacies across the country. Through a strategic partnership with a German company, Relevium is working to have several formulations registered under a PZN and plans to market these products available through pharmacies and major health portals.

Relevium has also been aggressively pursuing South American opportunities. Initially, Biocannabix was focused on building out a facility in Canada but the high costs associated with this project, the company to pivot its strategy. Instead, Biocannabix is looking away from cultivation, at other segments of the industry with the Weedsense transaction, while securing and controlling plant genetics and extracts from South America. We are favorable on the economics associated with cultivation in South America and will monitor how the team is able to execute on this opportunity.

An Opportunity to be Watching

When looking at Relevium Technologies, we see an under-appreciated opportunity that has significant catalysts for growth. We believe that the recent pressure on the stock is waning and we see the tides potentially turning for Relevium Technologies.      The US symbol (OTCQB: RLLVF) recently received DTC edibility     .

During the last year, Relevium has reported several significant developments and has been generating much stronger revenues. This is an important trend and one that we will continue to monitor. We expect to see continued growth as the company’s products continue to gain traction and find this to be significant. The recent investments and acquisitions have significantly enhanced the company’s overall growth prospects, and this is an opportunity that we will continue to closely monitor.

If you are interested in staying up to date with Relevium Technologies, please contact


Share - Facebook

Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Fri, 14 Jun 2019 10:05:28 +0000

Affiliate of Canadian firm Hexo wins Greek cannabis license

Affiliate of Canadian firm Hexo wins Greek cannabis license

An affiliate of Quebec-based cannabis producer Hexo has received a license allowing it to establish cultivation, processing and manufacturing facilities in Greece, the company announced Thursday.

Greece aims to compete with Denmark, Portugal and Malta as a hub to meet demand for medical cannabis in Europe.

The affiliate, Hexo Med, is planning to construct a greenhouse and other facilities on a 700,000-square-foot plot in Larissa, Greece.

Construction of a roughly 320,000-square-foot facility is expected to start in the fourth quarter, the company said.

Meanwhile, Hexo reported third-quarter 2019 financial results.

The company’s gross cannabis revenue declined in the quarter ending April to 15.9 million Canadian dollars ($11.9 million) from the previous quarter’s CA$16.1 million.

Hexo reported net revenue of CA$13 million for the quarter, which New York-based investment bank Jefferies said was below consensus estimates.

The Quebec company said it is on track to sell CA$400 million of marijuana products in the next fiscal year.

Hexo also said it plans to launch hemp-based products in eight American states next year.

The company trades as HEXO on the Toronto Stock Exchange and New York Stock Exchange.

Published at Thu, 13 Jun 2019 20:40:28 +0000

Marijuana Stocks Review

Marijuana Stocks Review

The marijuana industry has grown by leaps and bounds over the past year or so, primarily due to the legalization in Canada and in parts of the United States. The formation of the industry and the listing of stocks from many of the leading companies which have also made it possible for investors to put their money into a growing sector.

Some investors might prefer stocks which are on a strong streak of gains, while others might prefer a stock that are beaten down and could be primed for a surge soon. In such a situation, it is worthwhile to look at the stocks of two Canadian marijuana producers, Organigram Holdings (OGI) and CannTrust (CTST).


Organigram may have been a bit late when it comes to listing on a United States stock exchange but the company has had an excellent run in the market once it did. One of the most compelling reasons behind Organigram’s is the company’s low production costs and at the end of the day, investors will always be attracted to a company that can maintain such margins. Additionally, it is also set to raise its production capacity extensively this year.

Organigram expects to produce 113,000 kilos of marijuana this year, up from 47,000 kilos a year on average over the past years. Moreover, it has also been able to ink supply agreements with 10 major provinces in Canada and has also created an international footprint through its partnership with Alpha in Germany. Organigram is also making ground to enter the cannabis edibles market in a big way next year.


On the other hand, CannTrust is a highly interesting company and has been one of the bigger players in the medical marijuana market in Canada. More importantly, the company has also delivered exceptional growth in terms of the number of patients it services. In Q1 2019, the company reported a 70% year on year rise in patient growth.

More importantly, CannTrust has inked supply agreements with 9 states in Canada and due to its partnership with National Access Cannabis, the company’s products will reach an even bigger base of patients in the near future. It has also projected that it is going to produce 50,000 kilos of product a year from the next quarter onwards and it will go up once the Niagara facility expansion is completed. Last but not least, the company has also forayed into international markets through partnerships in Australia and Denmark.

According to experts, Organigram has grown quite rapidly, while CannTrust’s market cap is far smaller and hence could provide a bigger upside in the foreseeable future.

Published at Thu, 13 Jun 2019 19:53:42 +0000

Medical Marijuana Delivery

Your subscription could not be saved. Please try again.

Your subscription has been successful.

Subscribe now

Subscribe to our newsletter and stay updated.